Vaccine produces long-lasting anti-tumor response in patients with melanoma

Patients treated with a vaccine tailored to mutated proteins on patients' own tumor cells, continue to have a strong immune response to the cancer four years after being vaccinated. Results demonstrate the ability of personalized cancer vaccines to provide long-term immunity against some cancers.